Johnson & Johnson Invests $1 Billion in Firefly Bio to Develop KRAS Cancer Treatments
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
Image: Stat
Johnson & Johnson is acquiring Firefly Bio for $1 billion to enhance its KRAS inhibitor research. This move follows promising results from Revolution Medicines showing a KRAS-targeted drug could significantly improve survival rates in metastatic pancreatic cancer.
- 01Johnson & Johnson's acquisition of Firefly Bio aims to strengthen its position in KRAS inhibitor development.
- 02The $1 billion deal highlights the growing interest in KRAS-targeted therapies for cancer treatment.
- 03Revolution Medicines' recent success indicates the potential of KRAS inhibitors, especially for pancreatic cancer.
- 04Mutant KRAS genes are present in about 30% of all tumors, making them a critical target for cancer therapies.
- 05Previous attempts to develop KRAS inhibitors faced challenges in targeting the protein effectively.
Advertisement
In-Article Ad
Johnson & Johnson announced its acquisition of Firefly Bio for $1 billion to bolster its efforts in developing KRAS inhibitors, a promising area in cancer treatment. This strategic move follows recent findings from Revolution Medicines, which demonstrated that a KRAS-targeted drug could nearly double survival rates for patients with metastatic pancreatic cancer. The KRAS gene is implicated in approximately 30% of all tumors, making it a significant focus for drug developers. Historically, targeting the KRAS protein has been challenging, likened to trying to grasp a 'greasy ball,' but recent advancements have reignited interest in this critical area of oncology.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of KRAS inhibitors in cancer treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.